A randomized phase III study comparing gemcitabine monotherapy with observation in patients with resected pancreatic cancer

被引：1
|
作者：
Kosuge, T. [1 ]
Ueno, H. [1 ]
Matsuyama, Y. [2 ]
Yamamoto, J. [3 ]
Nakao, A. [4 ]
Egawa, S. [5 ]
Doi, R. [6 ]
Monden, M. [7 ]
Hatori, T. [8 ]
Tanaka, M. [9 ]
机构：
[1] Natl Canc Ctr, Hepatobiliary & Pancreat Surg Div, Tokyo, Japan
[2] Univ Tokyo, Dept Biostat, Tokyo, Japan
[3] Canc Inst Hosp, Dept Gastrointestinal Surg, Tokyo, Japan
[4] Nagoya Univ, Dept Surg 2, Aichi, Japan
[5] Tohoku Univ, Div Gastroenterol, Sendai, Miyagi 980, Japan
[6] Kyoto Univ, Dept Surg, Kyoto, Japan
[7] Osaka Univ, Dept Surg & Clin Oncol, Osaka, Japan
[8] Tokyo Womens Med Univ, Dept Surg, Tokyo, Japan
[9] Kyushu Univ, Dept Surg & Oncol, Fukuoka 812, Japan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71007-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3504
引用
收藏
页码：260 / 260
页数：1
相关论文
共 50 条
  • [31] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Stefan Heinrich
    Bernhard Pestalozzi
    Mickael Lesurtel
    Frederik Berrevoet
    Stéphanie Laurent
    Jean-Robert Delpero
    Jean-Luc Raoul
    Phillippe Bachellier
    Patrick Dufour
    Markus Moehler
    Achim Weber
    Hauke Lang
    Xavier Rogiers
    Pierre-Alain Clavien
    BMC Cancer, 11
  • [32] Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
    Heinemann, Volker
    Quietzsch, Detlef
    Gieseler, Frank
    Gonnermann, Michael
    Schoenekaes, Herbert
    Rost, Andreas
    Neuhaus, Horst
    Haag, Caroline
    Clemens, Michael
    Heinrich, Bernard
    Vehling-Kaiser, Ursula
    Fuchs, Martin
    Fleckenstein, Doris
    Gesierich, Wolfgang
    Uthgenannt, Dirk
    Einsele, Hermann
    Holstege, Axel
    Hinke, Axel
    Schalhorn, Andreas
    Wilkowski, Ralf
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3946 - 3952
  • [33] A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201
    Loehrer, P. J., Sr.
    Powell, M. E.
    Cardenes, H. R.
    Wagner, L.
    Brell, J. M.
    Ramanathan, R. K.
    Crane, C. H.
    Alberts, S. R.
    Benson, A. B., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Randomized phase II study of best available fluoropyrimidine compared with continuation of gemcitabine (Gem) monotherapy in patients with Gem-refractory pancreatic cancer
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Ishida, Nobuko
    Takada, Ryoji
    Yamai, Takuo
    Fukutake, Nobuyasu
    Ashida, Reiko
    Uehara, Hiroyuki
    Ohigashi, Hiroaki
    Takahashi, Hidenori
    Ishikawa, Osamu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [35] Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
    Neoptolemos, John P.
    Palmer, Daniel H.
    Ghaneh, Paula
    Psarelli, Eftychia E.
    Valle, Juan W.
    Halloran, Christopher M.
    Faluyi, Olusola
    O'Reilly, Derek A.
    Cunningham, David
    Wadsley, Jonathan
    Darby, Suzanne
    Meyer, Tim
    Gillmore, Roopinder
    Anthoney, Alan
    Lind, Pehr
    Glimelius, Bengt
    Falk, Stephen
    Izbicki, Jakob R.
    Middleton, Gary William
    Cummins, Sebastian
    Ross, Paul J.
    Wasan, Harpreet
    McDonald, Alec
    Crosby, Tom
    Ma, Yuk Ting
    Patel, Kinnari
    Sherriff, David
    Soomal, Rubin
    Borg, David
    Sothi, Sharmila
    Hammel, Pascal
    Hackert, Thilo
    Jackson, Richard
    Buechler, Markus W.
    LANCET, 2017, 389 (10073): : 1011 - 1024
  • [36] A randomized phase II trial of adjuvant chemotherapy with uracil / tegafur (UFT) and gemcitabine (GEM) vs. gemcitabine alone in patients with resected pancreatic cancer
    Yoshitomi, H.
    Togawa, A.
    Kimura, F.
    Shimizu, H.
    Yoshidome, H.
    Miyazaki, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
    Scott, Aaron James
    O'Neil, Bert H.
    Ma, Wen Wee
    Cohen, Steven J.
    Aisner, Dara
    Menter, Alex R.
    Tejani, Mohamedtaki Abdulaziz
    Cho, Jonathan K.
    Rubin, Peter
    Coveler, Andrew L.
    Olowokure, Olugbenga Olanrele
    Baranda, Joaquina Celebre
    Cusnir, Mike
    Philip, Philip Agop
    Boles, Jeremiah
    Maguire, Robert T.
    Wilhelm, Francois
    Maniar, Manoj
    Gomes, Christina
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001).
    Ueno, M.
    Ohkawa, S.
    Sugimori, K.
    Kobayashi, S.
    Kaneko, T.
    Taguri, M.
    Morita, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase II study of gemcitabine in patients with advanced pancreatic cancer
    Carmichael, J
    Fink, U
    Russell, RCG
    Spittle, MF
    Harris, AL
    Spiessi, G
    Blatter, J
    BRITISH JOURNAL OF CANCER, 1996, 73 (01) : 101 - 105
  • [40] Systemic inflammatory response to predict clinical outcome in patients with resected pancreatic cancer treated with adjuvant gemcitabine monotherapy.
    Morinaga, Soichiro
    Watanabe, Takuo
    Numata, Masakatsu
    Mikayama, Yo
    Tamagawa, Hiroshi
    Yamamoto, Naoto
    Shiozawa, Manabu
    Akaike, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345